ArticleFrontiers in physiology2026
Predictive value of the C-reactive protein-to-lymphocyte ratio for prognosis in heart failure patients with acute kidney injury.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic value of the C-reactive protein-to-lymphocyte ratio (CLR) in critical and inflammatory diseases is increasingly recognized. Nonetheless, its role in risk stratification for patients with congestive heart failure (CHF) who develop acute kidney injury (AKI) has not been thoroughly investigated. Research indicates that cardiorenal syndrome is mediated by a cytokine storm causing cardiac and renal injury, the extent of which can be quantified by the CLR and is significantly associated with adverse outcomes such as mortality and cardiovascular events. This study aims to elucidate the relationship between CLR and mortality in this patient population. Methods: Leveraging data from the MIMIC-IV database, we identified patients diagnosed with both CHF and AKI. We employed Cox models to gauge the link between CLR and near- and long-term (30-day/365-day) all-cause mortality, supplemented by Kaplan-Meier analysis across CLR quartiles. The non-linear dynamics of this relationship were mapped with restricted cubic splines (RCS). The model's predictive performance was appraised using ROC curves, and potential effect modifiers were probed through comprehensive subgroup analyses to elucidate the interplay of key factors. Results: Among 1605 patients, higher CLR quartiles were associated with significantly worse survival by Kaplan-Meier analysis (log-rank P < 0.001). After full multivariable adjustment, the risk of 365-day mortality increased progressively across CLR quartiles (Q2: HR 1.96 [1.33-2.90]; Q3: 2.19 [1.49-3.21]; Q4: 3.78 [2.63-5.43]; P-trend < 0.001). Similar trends were observed for 30-day mortality (Q4: 4.32 [2.19-8.53]; P-trend < 0.001), although the HRs for Q2 and Q3 did not reach statistical significance. Fully adjusted RCS confirmed linear LnCLR-mortality associations for 30-day (P for nonlinearity = 0.352) and 365-day outcomes (P for nonlinearity = 0.197). ROC analysis demonstrated fair discriminative ability of CLR for 30-day (AUC: 0.713) and 365-day mortality (AUC: 0.675). Subgroup analyses confirmed consistent prognostic effects (all P for interaction > 0.05). Conclusion: CLR independently is associated with both short- and long-term mortality in CHF-AKI patients, supporting its clinical utility for risk stratification in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.